公开(公告)号：EP4190322A1

公开(公告)日：2023-06-07

申请号：EP21850238.3

申请日：2021-07-29

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Shaoxing Zeroin Biomedicines Co., Ltd.

发明人： YANG, Huaiyu ,  LI, Yang ,  GUO, Fei ,  JIANG, Hualiang ,  ZHANG, Qiansen

IPC分类号： A61K31/18 ,  A61K31/136 ,  A61K31/137 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K9/72 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24

摘要： Provided are a compound for preventing and treating psychiatric disorders and the use thereof. In particular, provided is the use of a compound of formula I or a pharmaceutically acceptable salt thereof in (i) the preparation of a pharmaceutical composition or a preparation for preventing and/or treating TREK-1 ion channel-related diseases, (ii) the preparation of a pharmaceutical composition or a preparation for preventing and/or treating psychiatric disorders and/or (iii) the preparation of a TREK-1 ion channel inhibitor.

公开(公告)号：EP3835296A1

公开(公告)日：2021-06-16

申请号：EP19847084.1

申请日：2019-08-09

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Fudan University

发明人： LIU, Hong ,  JIANG, Shibo ,  DAI, Wenhao ,  LU, Lu ,  PENG, Jingjing ,  XIA, Shuai ,  WANG, Jiang ,  LI, Jian ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： C07D403/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D241/44 ,  C07D209/42 ,  A61K31/498 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4025 ,  A61K31/4525 ,  A61K31/4709 ,  A61P31/14

摘要： A ketoamide compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically, the ketoamide compound shown in formula (A), a racemate, an enantiomer, or a diastereoisomer thereof, or any mixture of same, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The ketoamide compound can effectively inhibit coronavirus or Ebola virus, and thereby implement the prevention or treatment of diseases related to coronavirus or diseases related to Ebola virus.

公开(公告)号：EP3798218A1

公开(公告)日：2021-03-31

申请号：EP19806732.4

申请日：2019-05-21

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LIU, Hong ,  GENG, Meiyu ,  ZHOU, Yu ,  DING, Jian ,  FANG, Feifei ,  AI, Jing ,  LI, Jian ,  PENG, Xia ,  JIANG, Hualiang ,  JI, Yinchun ,  CHEN, Kaixian

IPC分类号： C07D471/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D453/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/5025 ,  A61K31/4985 ,  A61K31/4709 ,  A61P35/00

摘要： Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

公开(公告)号：EP3741758A1

公开(公告)日：2020-11-25

申请号：EP19740997.2

申请日：2019-01-11

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Suzhou Suplead Life Sciences Co., Ltd.

发明人： ZHOU, Bing ,  LUO, Cheng ,  LI, Zizhou ,  YANG, Yaxi ,  CHEN, Shijie ,  DING, Hong ,  JIANG, Hualiang ,  QIAO, Gang ,  WANG, Xinjun ,  XIAO, Senhao

IPC分类号： C07D487/04 ,  A61K31/53 ,  A61P35/00

摘要： The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.

公开(公告)号：EP3214079B1

公开(公告)日：2020-06-24

申请号：EP15855852.8

申请日：2015-10-30

申请人： East China University Of Science And Technology ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LI, Honglin ,  JIANG, Hualiang ,  XU, Yufang ,  LI, Jia ,  ZHAO, Zhenjiang ,  LI, Jingya ,  XU, Hongling ,  LI, Shiliang

IPC分类号： C07D311/92 ,  C07D405/04 ,  C07D417/04 ,  C07D221/10 ,  C07D335/04 ,  A61K31/352 ,  A61K31/5377 ,  A61P3/00 ,  A61P3/10 ,  A61P7/10 ,  A61P29/00

公开(公告)号：EP3284738A1

公开(公告)日：2018-02-21

申请号：EP16779633.3

申请日：2016-04-15

申请人： Shanghai Institute Of Materia Medica Chinese Academy of Sciences

发明人： LIU, Hong ,  ZHOU, Yu ,  ZHANG, Dong ,  LI, Jian ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： C07D213/56 ,  C07D401/12 ,  C07D277/30 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D417/06 ,  C07D213/82 ,  C07D213/75 ,  C07D239/26

CPC分类号： C07D487/04 ,  C07D213/56 ,  C07D213/75 ,  C07D213/82 ,  C07D231/56 ,  C07D239/26 ,  C07D261/08 ,  C07D263/32 ,  C07D277/30 ,  C07D277/32 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D491/10

摘要： The present invention relates to the fields of pharmaceutical chemistry and drug therapy, and particularly relates to a compound of formula I, and a preparation method and use thereof as a negative allosteric modulator of a metabotropic glutamate receptor (mG1uR) subtype 5.

摘要翻译： 本发明涉及药物化学和药物治疗领域，具体涉及作为代谢型谷氨酸受体（mG1uR）亚型5的负变构调节剂的式I化合物及其制备方法和用途。

公开(公告)号：EP3120847A1

公开(公告)日：2017-01-25

申请号：EP15765481.5

申请日：2015-03-17

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Nanjing Pailexing Pharmaceutical Technology Ltd.

发明人： ZHU, Weiliang ,  WANG, Heyao ,  ZHANG, Yong ,  SUN, Peng ,  LI, Bo ,  XU, Zhijian ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： A61K31/352 ,  A61K36/53 ,  A61P3/10 ,  A61P3/06 ,  A61P3/04 ,  A61P13/12

CPC分类号： A61K31/7048 ,  A61K36/53 ,  A61K2236/30 ,  A61K2236/53

摘要： Disclosed is a Glechoma longituba (Nakai) Kupr . extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.

摘要翻译： 披露是一种Glechoma longituba（Nakai）Kupr。 提取物，特别是化合物I和II，其制备方法，以及其在制备用于血糖降低，血脂降低，体重减轻和肾脏疾病治疗的药物中的用途或用于治疗所述疾病的方法， 含有提取物。

公开(公告)号：EP2848617A1

公开(公告)日：2015-03-18

申请号：EP13787305.5

申请日：2013-05-09

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LIU, Hong ,  ZHEN, Xuechu ,  SUN, Haifeng ,  ZHU, Liyuan ,  QIAN, Wangke ,  YU, Leiping ,  LI, Zeng ,  ZHOU, Shengbin ,  CAI, Wenxian ,  JIANG, Hualiang ,  CHEN, Kaixian

IPC分类号： C07D455/03 ,  A61K31/4375 ,  A61P25/00 ,  A61P25/18

CPC分类号： C07D471/14 ,  C07D455/03 ,  C07D491/147 ,  C07D491/22 ,  C07D495/14 ,  C07D495/22

摘要： The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

摘要翻译： 本发明涉及式（I）的二芳基[a，g]喹唑啉化合物，其对映体，非对映异构体，外消旋体，混合物，药学上可接受的盐，结晶水合物或溶剂化物; 其制备方法及其在制备与多巴胺受体和5-HT受体有关的实验模型药物或用于治疗或预防与多巴胺受体和5-HT受体有关的疾病的药物中的用途。

公开(公告)号：EP2383262A1

公开(公告)日：2011-11-02

申请号：EP09831388.5

申请日：2009-12-10

申请人： Topharman Shanghai Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Topharman Shandong Co., Ltd.

发明人： LIU, Zheng ,  LI, Jianfeng ,  YANG, Xiaojun ,  WANG, Zhen ,  ZHANG, Jinfeng ,  ZHU, Yi ,  TIAN, Guanghui ,  JIN, Qing ,  SHEN, Jingkang ,  ZHU, Weiliang ,  JIANG, Hualiang ,  SHEN, Jingshan

IPC分类号： C07D239/36 ,  A61K31/505 ,  A61P15/10

CPC分类号： A61K31/505 ,  C07D239/36 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07H15/26

摘要： The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof; and to the pharmaceutical composition as well as the preparation method of the said compounds. The said compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.

摘要翻译： 本发明涉及一类苯基嘧啶酮化合物，药物组合物，其制备方法及用途。 更具体地，本发明涉及一种下式I的苯基嘧啶酮化合物，其药学上可接受的盐或溶剂合物; 和药物组合物以及所述化合物的制备方法。 所述根据本发明的式I化合物可有效抑制V型磷酸二酯酶（PDE5），因此可用于治疗各种血管疾病，如男性勃起功能障碍，肺动脉高压等。

公开(公告)号：EP4178586A1

公开(公告)日：2023-05-17

申请号：EP21837572.3

申请日：2021-07-08

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Hangzhou Leading Edge Pharmaceutical Ltd. ,  SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED

发明人： LUO, Cheng ,  XU, Meng ,  CHEN, Shijie ,  LI, Yilin ,  CHEN, Yantao ,  JIANG, Hualiang ,  CHEN, Kaixian ,  JIANG, Zhanpeng

IPC分类号： A61K31/7088 ,  A61K38/55 ,  C07K16/06 ,  A61K39/00